ERNA

Eterna Therapeutics Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies using messenger ribonucleic acid (RNA) (mRNA) cell engineering technology. The Company has a portfolio of over 100 patents covering mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system, which the Company collectively refers to as its mRNA technology platform. Its mRNA gene-editing technology is designed to delete, insert, and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to fight cancer.